SMARCA4 and adenocarcinoma: The last analysis from Liu et al. demonstrated significantly worse OS for all four SMARCA4/KRAS-mutated adenocarcinoma NSCLC cohorts across ICI-treated and non-ICI-treated NSCLC patients [37].